Pulmonary Drug Delivery Systems: Technologies and Global Markets
Report Scope:
This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, R&D pipeline and blockbuster drugs.
In the report, the regulatory scenario of pulmonary drug delivery systems is discussed for each device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are also analyzed.
The report includes profiles of major companies in the market for pulmonary drug delivery systems, with overviews of their key product offerings and financials.
Report Includes:
This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, R&D pipeline and blockbuster drugs.
In the report, the regulatory scenario of pulmonary drug delivery systems is discussed for each device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are also analyzed.
The report includes profiles of major companies in the market for pulmonary drug delivery systems, with overviews of their key product offerings and financials.
Report Includes:
- 44 tables
- A brief overview and up-to-date analysis of the global markets for pulmonary drug delivery systems
- Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation of the actual market size and revenue forecast for pulmonary drug delivery systems in USD value terms, and their corresponding market share analysis by type of drug delivery systems, application/disease area and region
- Highlights of the major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis; also, an industry-wide assessment of the key developments, novel products, recent approvals, R&D activities, pipeline products and blockbuster drugs
- In-depth information (facts and figures) concerning market drivers, opportunities and challenges, and other macroeconomic forces affecting the global pulmonary drug delivery systems market
- Holistic review of the international regulatory landscape for pulmonary drug delivery systems with emphasis on recently approved products as well as products under development or in different stages of clinical trials
- Updated information on key mergers and acquisition deals, agreements, collaborations and other impactful strategies adopted by key players in the global pulmonary drug delivery systems market
- Assessment of the recent patents published and granted on pulmonary drug delivery systems and related technologies
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
- Descriptive company profiles of the market leading players, including Abbott, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Lupin and Pfizer Inc.
CHAPTER 1 INTRODUCTION
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 What's New in This Update?
1.4 Scope of Report
1.5 Information Sources
1.5.1 Secondary Research
1.5.2 Primary Research
1.6 Methodology
1.7 Geographic Breakdown
1.8 Analyst's Credentials
1.9 BCC Custom Research
1.10 Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND
3.1 Market Definition and Overview
3.1.1 Mechanism of Action
3.1.2 Advantages
3.1.3 Limitations/Challenges
3.2 Pulmonary Conditions and Therapies
3.2.1 Introduction to the Respiratory System
3.3 Market Drivers and Trends
3.3.1 Improved Patient Compliance and Ease of Use
3.3.2 Cost Pressures on Countries
3.3.3 Rising Incidence of Asthma
3.3.4 Causes
3.3.5 Reducing the Burden of Asthma
3.4 Market Restraints
3.4.1 Competition from Generics on the Rise
3.5 Market Opportunities
3.5.1 Introduction of Smart Nebulizers
3.6 Regulation and Legislation
3.6.1 U.S.
CHAPTER 4 MARKET BREAKDOWN BY PULMONARY DRUG DELIVERY SYSTEMS
4.1 Overview of Inhalation Techniques
4.2 Dry Powder Inhalers (DPIs)
4.2.1 Overview
4.2.2 Marketed Products
4.3 Metered Dose Inhalers (MDIs)
4.3.1 Overview
4.3.2 Marketed Products
4.4 Nebulizers
4.4.1 Overview
4.4.2 Marketed Products Overview by Manufacturer
CHAPTER 5 COVID-19 IMPACT
5.1 Overview
5.2 COVID-19 Crisis
5.3 Impact on Market for Pulmonary Drug Delivery Systems
5.4 Current Outlook
CHAPTER 6 PULMONARY DRUG DELIVERY SYSTEMS IN USE
6.1 Therapeutic Agents Administered via Inhalation
6.1.1 Steroids
6.1.2 Bronchodilators
CHAPTER 7 MARKET BREAKDOWN BY DISEASE AREA
7.1 Introduction
7.2 Asthma
7.2.1 Asthma Attacks
7.2.2 Asthma and Obesity
7.2.3 Mortality
7.2.4 Disease Classification
7.2.5 Diagnosis
7.2.6 Treatment and Therapies
7.2.7 Market Size and Forecasts
7.3 Chronic Obstructive Pulmonary Disease (COPD)
7.3.1 Diagnosis
7.3.2 Treatment and Therapies
7.3.3 Market Size and Forecasts
7.4 Other Diseases
7.4.1 Market Size and Forecasts
CHAPTER 8 MARKET BREAKDOWN BY REGION
8.1 North America
8.1.1 U.S.
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 U.K.
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 South Korea
8.3.5 Rest of Asia-Pacific
8.4 Rest of the World
8.5 South America
CHAPTER 9 PATENT ANALYSIS
9.1 Overview
CHAPTER 10 COMPANY PROFILES
3M
ABBOTT LABORATORIES
ASTRAZENECA
BOEHRINGER INGELHEIM GMBH
CIPLA
DR. REDDY'S LABORATORIES LTD.
GLAXOSMITHKLINE PLC
PHILIPS RESPIRONICS
LUPIN
MYLAN N.V.
MERCK KGAA
NOVARTIS AG
OMRON CORP.
PFIZER INC.
PULMATRIX INC.
TEVA PHARMACEUTICALS INDUSTRIES LTD.
CHAPTER 11 APPENDIX: ABBREVIATIONS
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 What's New in This Update?
1.4 Scope of Report
1.5 Information Sources
1.5.1 Secondary Research
1.5.2 Primary Research
1.6 Methodology
1.7 Geographic Breakdown
1.8 Analyst's Credentials
1.9 BCC Custom Research
1.10 Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND
3.1 Market Definition and Overview
3.1.1 Mechanism of Action
3.1.2 Advantages
3.1.3 Limitations/Challenges
3.2 Pulmonary Conditions and Therapies
3.2.1 Introduction to the Respiratory System
3.3 Market Drivers and Trends
3.3.1 Improved Patient Compliance and Ease of Use
3.3.2 Cost Pressures on Countries
3.3.3 Rising Incidence of Asthma
3.3.4 Causes
3.3.5 Reducing the Burden of Asthma
3.4 Market Restraints
3.4.1 Competition from Generics on the Rise
3.5 Market Opportunities
3.5.1 Introduction of Smart Nebulizers
3.6 Regulation and Legislation
3.6.1 U.S.
CHAPTER 4 MARKET BREAKDOWN BY PULMONARY DRUG DELIVERY SYSTEMS
4.1 Overview of Inhalation Techniques
4.2 Dry Powder Inhalers (DPIs)
4.2.1 Overview
4.2.2 Marketed Products
4.3 Metered Dose Inhalers (MDIs)
4.3.1 Overview
4.3.2 Marketed Products
4.4 Nebulizers
4.4.1 Overview
4.4.2 Marketed Products Overview by Manufacturer
CHAPTER 5 COVID-19 IMPACT
5.1 Overview
5.2 COVID-19 Crisis
5.3 Impact on Market for Pulmonary Drug Delivery Systems
5.4 Current Outlook
CHAPTER 6 PULMONARY DRUG DELIVERY SYSTEMS IN USE
6.1 Therapeutic Agents Administered via Inhalation
6.1.1 Steroids
6.1.2 Bronchodilators
CHAPTER 7 MARKET BREAKDOWN BY DISEASE AREA
7.1 Introduction
7.2 Asthma
7.2.1 Asthma Attacks
7.2.2 Asthma and Obesity
7.2.3 Mortality
7.2.4 Disease Classification
7.2.5 Diagnosis
7.2.6 Treatment and Therapies
7.2.7 Market Size and Forecasts
7.3 Chronic Obstructive Pulmonary Disease (COPD)
7.3.1 Diagnosis
7.3.2 Treatment and Therapies
7.3.3 Market Size and Forecasts
7.4 Other Diseases
7.4.1 Market Size and Forecasts
CHAPTER 8 MARKET BREAKDOWN BY REGION
8.1 North America
8.1.1 U.S.
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 U.K.
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 South Korea
8.3.5 Rest of Asia-Pacific
8.4 Rest of the World
8.5 South America
CHAPTER 9 PATENT ANALYSIS
9.1 Overview
CHAPTER 10 COMPANY PROFILES
3M
ABBOTT LABORATORIES
ASTRAZENECA
BOEHRINGER INGELHEIM GMBH
CIPLA
DR. REDDY'S LABORATORIES LTD.
GLAXOSMITHKLINE PLC
PHILIPS RESPIRONICS
LUPIN
MYLAN N.V.
MERCK KGAA
NOVARTIS AG
OMRON CORP.
PFIZER INC.
PULMATRIX INC.
TEVA PHARMACEUTICALS INDUSTRIES LTD.
CHAPTER 11 APPENDIX: ABBREVIATIONS
LIST OF TABLES
Summary Table A: Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027
Summary Table B: Global Market for Pulmonary Drug Delivery Systems, by Region, Through 2027
Table 1: Key Products Going Off-Patent, 2020-2030
Table 2: Inhaler Device Characteristics
Table 3: Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027
Table 4: Capsule-based Inhaler Devices
Table 5: Blister-based Inhaler Devices
Table 6: Reservoir/Cartridge-based Inhaler Devices
Table 7: MDIs, HFA Propellant
Table 8: MDIs, Anti-Inflammatory Medicine
Table 9: MDIs, Combination Medicine
Table 10: Commonly Used MDIs
Table 11: Comparison of Nebulizers
Table 12: Marketed Nebulizers by Manufacturer
Table 13: Total Number of COVID-19 Confirmed Cases and Deaths, by Region, June 2022
Table 14: COVID-19 Confirmed Cases and Deaths Globally, by Country, June 20, 2022
Table 15: Inhaled Steroids
Table 16: Inhaled Corticosteroids
Table 17: Inhaled Corticosteroids, Combination Inhalers
Table 18: Short-Acting Inhaled Beta-Agonist (SABA) Bronchodilators
Table 19: Short-Acting Inhaled Muscarinic Antagonist (SAMA) and SABA Combination Bronchodilators
Table 20: Long-Acting Inhaled Beta-2 Agonists (LABA) Bronchodilators
Table 21: Long-Acting Inhaled Muscarinic Antagonists (LAMA) Bronchodilators
Table 22: LABA and LAMA Combination Bronchodilators
Table 23: Global Asthma Market, Through 2027
Table 24: Leading Causes of Death Worldwide, 2020
Table 25: Global COPD Market, Through 2027
Table 26: Global Market for Other Pulmonary Diseases, Through 2022
Table 27: Prevalence of Asthma, by Race and Ethnicity in Americans
Table 28: European Self-Reported Asthma, 2020
Table 29: European Self-Reported COPD, 2020
Table 30: Leading Causes of Death in Australia, 2020 and 2021
Table 31: Key Patents, Pulmonary Drug Delivery Systems
Table 32: 3M: Key Developments
Table 33: Abbott: Product Portfolio by Business Segment, 2021
Table 34: Abbott: Key Developments
Table 35: AstraZeneca PLC: Key Developments
Table 36: Royal Philips: List of Subsidiaries
Table 37: Philips Health: Business Segments
Table 38: Lupin: Key Developments
Table 39: Novartis AG: Key Developments
Table 40: Pfizer Inc.: Key Developments
Table 41: Teva: Key Developments
Table 42: Abbreviations Used in Pulmonary Drug Delivery Systems
Summary Table A: Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027
Summary Table B: Global Market for Pulmonary Drug Delivery Systems, by Region, Through 2027
Table 1: Key Products Going Off-Patent, 2020-2030
Table 2: Inhaler Device Characteristics
Table 3: Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027
Table 4: Capsule-based Inhaler Devices
Table 5: Blister-based Inhaler Devices
Table 6: Reservoir/Cartridge-based Inhaler Devices
Table 7: MDIs, HFA Propellant
Table 8: MDIs, Anti-Inflammatory Medicine
Table 9: MDIs, Combination Medicine
Table 10: Commonly Used MDIs
Table 11: Comparison of Nebulizers
Table 12: Marketed Nebulizers by Manufacturer
Table 13: Total Number of COVID-19 Confirmed Cases and Deaths, by Region, June 2022
Table 14: COVID-19 Confirmed Cases and Deaths Globally, by Country, June 20, 2022
Table 15: Inhaled Steroids
Table 16: Inhaled Corticosteroids
Table 17: Inhaled Corticosteroids, Combination Inhalers
Table 18: Short-Acting Inhaled Beta-Agonist (SABA) Bronchodilators
Table 19: Short-Acting Inhaled Muscarinic Antagonist (SAMA) and SABA Combination Bronchodilators
Table 20: Long-Acting Inhaled Beta-2 Agonists (LABA) Bronchodilators
Table 21: Long-Acting Inhaled Muscarinic Antagonists (LAMA) Bronchodilators
Table 22: LABA and LAMA Combination Bronchodilators
Table 23: Global Asthma Market, Through 2027
Table 24: Leading Causes of Death Worldwide, 2020
Table 25: Global COPD Market, Through 2027
Table 26: Global Market for Other Pulmonary Diseases, Through 2022
Table 27: Prevalence of Asthma, by Race and Ethnicity in Americans
Table 28: European Self-Reported Asthma, 2020
Table 29: European Self-Reported COPD, 2020
Table 30: Leading Causes of Death in Australia, 2020 and 2021
Table 31: Key Patents, Pulmonary Drug Delivery Systems
Table 32: 3M: Key Developments
Table 33: Abbott: Product Portfolio by Business Segment, 2021
Table 34: Abbott: Key Developments
Table 35: AstraZeneca PLC: Key Developments
Table 36: Royal Philips: List of Subsidiaries
Table 37: Philips Health: Business Segments
Table 38: Lupin: Key Developments
Table 39: Novartis AG: Key Developments
Table 40: Pfizer Inc.: Key Developments
Table 41: Teva: Key Developments
Table 42: Abbreviations Used in Pulmonary Drug Delivery Systems
LIST OF FIGURES
Summary Figure: Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027
Figure 1: Smoking in Adults, by Region, 2020
Figure 2: Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027
Figure 3: Non-Communicable Disease Mortality Share, by Cause of Death, 2021
Figure 4: Global Asthma Market, 2019-2027
Figure 5: Global COPD Market, 2019-2027
Figure 6: Global Market for Other Pulmonary Diseases, 2019-2027
Figure 7: North American Pulmonary Drug Delivery Systems Market, 2019-2027
Figure 8: Health Issues in the Mexican Population, Proportional Mortality, 2020
Figure 9: Annual Mortality Rate for Asthma, by Country, 2020
Figure 10: European Pulmonary Drug Delivery Systems Market, 2019-2027
Figure 11: U.K. Mortality, by Disease 2021
Figure 12: Leading Causes of Death in Italy, Percentage Change, 2020
Figure 13: Leading Causes of Death in Rest of Europe Region, 2021
Figure 14: Asia-Pacific Pulmonary Drug Delivery Systems Market, 2019-2027
Figure 15: Annual Mortality Rates in Middle East and Africa, by Disease, 2020
Figure 16: Rest of the World Pulmonary Drug Delivery Systems Market, 2019-2027
Figure 17: Abbott: Annual Revenue, 2018-2021
Figure 18: Abbott: Revenue Share, by Segment, 2021
Figure 19: AstraZeneca PLC: Annual Revenue, 2018-2020
Figure 20: AstraZeneca PLC: Revenue Share, by Therapy Areas, 2020
Figure 21: Dr. Reddy’s Laboratories Ltd.: Annual Revenue, 2018-2020
Figure 22: Dr. Reddy’s Laboratories Ltd.: Revenue Share, by Business Segment, 2020
Figure 23: GlaxoSmithKline PLC: Annual Revenue, 2018-2020
Figure 24: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2020
Figure 25: Lupin: Annual Revenue, 2018-2020
Figure 26: Merck KGaA: Annual Revenue, 2018-2020
Figure 27: Merck KGaA: Revenue Share, by Business Segment, 2020
Figure 28: Novartis AG: Annual Revenue, 2018-2020
Figure 29: Novartis AG: Revenue Share, by Division, 2020
Figure 30: Pfizer Inc.: Annual Revenue, 2018-2020
Figure 31: Teva: Annual Revenue, 2018-2020
Summary Figure: Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027
Figure 1: Smoking in Adults, by Region, 2020
Figure 2: Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027
Figure 3: Non-Communicable Disease Mortality Share, by Cause of Death, 2021
Figure 4: Global Asthma Market, 2019-2027
Figure 5: Global COPD Market, 2019-2027
Figure 6: Global Market for Other Pulmonary Diseases, 2019-2027
Figure 7: North American Pulmonary Drug Delivery Systems Market, 2019-2027
Figure 8: Health Issues in the Mexican Population, Proportional Mortality, 2020
Figure 9: Annual Mortality Rate for Asthma, by Country, 2020
Figure 10: European Pulmonary Drug Delivery Systems Market, 2019-2027
Figure 11: U.K. Mortality, by Disease 2021
Figure 12: Leading Causes of Death in Italy, Percentage Change, 2020
Figure 13: Leading Causes of Death in Rest of Europe Region, 2021
Figure 14: Asia-Pacific Pulmonary Drug Delivery Systems Market, 2019-2027
Figure 15: Annual Mortality Rates in Middle East and Africa, by Disease, 2020
Figure 16: Rest of the World Pulmonary Drug Delivery Systems Market, 2019-2027
Figure 17: Abbott: Annual Revenue, 2018-2021
Figure 18: Abbott: Revenue Share, by Segment, 2021
Figure 19: AstraZeneca PLC: Annual Revenue, 2018-2020
Figure 20: AstraZeneca PLC: Revenue Share, by Therapy Areas, 2020
Figure 21: Dr. Reddy’s Laboratories Ltd.: Annual Revenue, 2018-2020
Figure 22: Dr. Reddy’s Laboratories Ltd.: Revenue Share, by Business Segment, 2020
Figure 23: GlaxoSmithKline PLC: Annual Revenue, 2018-2020
Figure 24: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2020
Figure 25: Lupin: Annual Revenue, 2018-2020
Figure 26: Merck KGaA: Annual Revenue, 2018-2020
Figure 27: Merck KGaA: Revenue Share, by Business Segment, 2020
Figure 28: Novartis AG: Annual Revenue, 2018-2020
Figure 29: Novartis AG: Revenue Share, by Division, 2020
Figure 30: Pfizer Inc.: Annual Revenue, 2018-2020
Figure 31: Teva: Annual Revenue, 2018-2020
